BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 21178018)

  • 1. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure.
    Ky B; French B; McCloskey K; Rame JE; McIntosh E; Shahi P; Dries DL; Tang WH; Wu AH; Fang JC; Boxer R; Sweitzer NK; Levy WC; Goldberg LR; Jessup M; Cappola TP
    Circ Heart Fail; 2011 Mar; 4(2):180-7. PubMed ID: 21178018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication.
    Ordu S; Ozhan H; Alemdar R; Aydin M; Caglar O; Yuksel H; Kandis H
    Tex Heart Inst J; 2012; 39(1):30-5. PubMed ID: 22412224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
    Lupón J; de Antonio M; Galán A; Vila J; Zamora E; Urrutia A; Bayes-Genis A
    Mayo Clin Proc; 2013 Mar; 88(3):234-43. PubMed ID: 23384388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.
    Zhang R; Zhang Y; Zhang J; An T; Huang Y; Guo X; Januzzi JL; Cappola TP; Yin S; Wang Y; Zhou Q; Zou C; Ji S; Lv R
    PLoS One; 2014; 9(10):e110976. PubMed ID: 25347817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP.
    Dhillon OS; Narayan HK; Quinn PA; Squire IB; Davies JE; Ng LL
    Am Heart J; 2011 Jun; 161(6):1163-70. PubMed ID: 21641364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.
    Pascual-Figal DA; Manzano-Fernández S; Boronat M; Casas T; Garrido IP; Bonaque JC; Pastor-Perez F; Valdés M; Januzzi JL
    Eur J Heart Fail; 2011 Jul; 13(7):718-25. PubMed ID: 21551163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.
    Sabatine MS; Morrow DA; Higgins LJ; MacGillivray C; Guo W; Bode C; Rifai N; Cannon CP; Gerszten RE; Lee RT
    Circulation; 2008 Apr; 117(15):1936-44. PubMed ID: 18378613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.
    Flores-Blanco PJ; Manzano-Fernández S; Pérez-Calvo JI; Pastor-Pérez FJ; Ruiz-Ruiz FJ; Carrasco-Sánchez FJ; Morales-Rull JL; Pascual-Figal D; Galisteo-Almeda L; Januzzi JL
    Clin Cardiol; 2015 Feb; 38(2):106-13. PubMed ID: 25663560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure.
    Bayes-Genis A; Pascual-Figal D; Januzzi JL; Maisel A; Casas T; Valdés Chávarri M; Ordóñez-Llanos J
    Rev Esp Cardiol; 2010 Oct; 63(10):1171-8. PubMed ID: 20875357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
    Suzuki S; Sugiyama S
    Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of diabetes on the predictive value of heart failure biomarkers.
    Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
    Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ST2 pathogenetic profile in ambulatory heart failure patients.
    Bayes-Genis A; Januzzi JL; Gaggin HK; de Antonio M; Motiwala SR; Zamora E; Galán A; Domingo M; Urrutia A; Lupón J
    J Card Fail; 2015 Apr; 21(4):355-61. PubMed ID: 25451702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
    Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
    Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple biomarkers for risk prediction in chronic heart failure.
    Ky B; French B; Levy WC; Sweitzer NK; Fang JC; Wu AH; Goldberg LR; Jessup M; Cappola TP
    Circ Heart Fail; 2012 Mar; 5(2):183-90. PubMed ID: 22361079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure.
    Adlbrecht C; Hülsmann M; Neuhold S; Strunk G; Pacher R
    J Heart Lung Transplant; 2013 May; 32(5):533-8. PubMed ID: 23453573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
    Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
    Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.
    Hao J; Cheang I; Zhang L; Wang K; Wang HM; Wu QY; Zhou YL; Zhou F; Xu DJ; Zhang HF; Yao WM; Li XL
    Chin Med J (Engl); 2019 Oct; 132(19):2278-2285. PubMed ID: 31567379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.
    Ahmad T; Fiuzat M; Neely B; Neely ML; Pencina MJ; Kraus WE; Zannad F; Whellan DJ; Donahue MP; Piña IL; Adams KF; Kitzman DW; O'Connor CM; Felker GM
    JACC Heart Fail; 2014 Jun; 2(3):260-8. PubMed ID: 24952693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.